Rocket One Inc. Common Stock (NASDAQ:RKTO) Stock Falls 4.5% – Should You Sell?

Rocket One Inc. Common Stock (NASDAQ:RKTO)’s stock price was down 4.5% during trading on Wednesday. The stock traded as low as $0.6645 and last traded at $0.67. Approximately 197,693 shares were traded during trading, a decline of 57% from the average session volume of 464,941 shares. The stock had previously closed at $0.7014.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Weiss Ratings upgraded Rocket One Inc. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, September 16th. Wall Street Zen lowered Rocket One Inc. Common Stock from a “sell” rating to a “strong sell” rating in a research report on Sunday, August 16th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $5.00.

Rocket One Inc. Common Stock Trading Down 4.5%

The stock has a market capitalization of $14.95 million, a P/E ratio of -0.82 and a beta of 0.90. The company’s 50-day moving average is $0.74 and its two-hundred day moving average is $0.84.

Rocket One Inc. Common Stock (NASDAQ:RKTO) last posted its earnings results on Friday, August 14th. The company reported ($0.19) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Rocket One Inc. Common Stock

An institutional investor recently raised its position in Rocket One Inc. Common Stock stock. Lido Advisors LLC boosted its holdings in Rocket One Inc. Common Stock (NASDAQ:RKTO) by 100.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 39,000 shares of the company’s stock after acquiring an additional 19,500 shares during the quarter. Lido Advisors LLC owned 0.20% of Rocket One Inc. Common Stock worth $33,000 at the end of the most recent quarter. 7.08% of the stock is owned by institutional investors and hedge funds.

About Rocket One Inc. Common Stock

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.